MétaCan
Menu
← Back to cohort
Record W4405042879 · doi:10.1182/blood-2024-201454

Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease

2024· article· en· W4405042879 on OpenAlexaff
Thiago Trovati Maciel, Haoua M Bazoum, Rachel Rignault‐Bricard, Shikha Saini, Isabelle Chevalme, Sara El Hoss, Robert Li, Slimane Allali, Rajasekhar N.V.S. Suragani, Olivier Hermine

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMicroRNA in disease regulation
Canadian institutionsSickKids FoundationHospital for Sick Children
Fundersnot available
KeywordsMedicineAnemiaDiseaseSickle cell anemiaCellPathologyInternal medicineBiology

Abstract

fetched live from OpenAlex

Introduction Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia and vaso-occlusive crises (VOC), leading to significant morbidity and mortality. Luspatercept is a ligand trap receptor indicated in thalassemia and myelodysplastic disease that restores effective erythropoiesis by reducing the inhibitory effects of transforming growth factor-beta (TGF-β) superfamily members, including GDF-11. Here we investigate the expression of GDF-11 in SCD patients and the role of RAP-536, a murine analog of luspatercept, in modulating anemia and VOC in SCD models, alone and/or in combination with hydroxyurea (HU) and epigenetic modulators Tazemetostat (TZM) and FTX6058, inducers of fetal hemoglobin (HbF). Methods We assessed GDF11 levels in plasma samples from SCD patients, healthy donors, and patients with other hemolytic anemias. Expression of GDF11 and pSMAD2 were evaluated in the spleen of Townes HbSS mice by immunohistochemistry. HbSS mice were treated with RAP-536 (1 or 10 mg/kg i.p. twice a week for 8 weeks), alone or in combination with hydroxyurea (100 mg/kg oral QD), TZM (250 mg/kg oral QD) and FTX6058 (20 mg/kg oral QD). Hematological, biochemical, and histological parameters were measured to assess treatment effects. Results Plasma GDF11 levels were significantly increased in SCD patients (27.7 pg/ml) when compared to healthy donors (5.0 pg/ml, p<0.01) and other hemolytic anemias (8.0 pg/ml). HbSS mice showed higher GDF11 expression in the spleen compared to HbAA mice, which correlated with SMAD2 phosphorylation. In HbSS mice, RAP-536 increased red blood cell (RBC) count and hemoglobin levels, decreased reticulocytes and ameliorated hemolytic markers, reducing lactate dehydrogenase (LDH), bilirubin as well as plasma free hemoglobin and plasma free heme. Likewise, tissue vascular congestion in hypoxia-induced VOC were reduced in the liver, lungs, and kidneys of HbSS mice upon RAP-536 treatment. Using ektacytometry, in vivo treatment of HSS mice by RAP-536 improved RBC deformability, as indicated by increased elongation index at 3Pa and 20Pa. This improvement correlated with enhanced oxygen carrying capacity in HbSS mice treated with RAP-536, with significant increases in total hemoglobin (+18.4%, p<0.05), oxygenated hemoglobin (+41.3%), oxygen saturation (+40.9%), oxygen content (+65.2%), and oxygen carrying capacity (+14.0%, p<0.05). All these effects were independent of HbF modulation. In contrast, RAP-536 significantly reduced blood reactive oxygen species (ROS) levels which may contribute to the reduction of VOC and improvement of erythropoiesis. RAP-536 reduced splenomegaly and improved erythropoietic maturation in spleen and bone marrow, indicated by a higher proportion of orthochromatic erythroblasts and reticulocytes (Ter-119+CD71− Ery.C) compared to late basophilic and polychromatic erythroblasts (Ter-119+CD71+ Ery.B). ROS level reduction was associated to increase in Nrf2 levels (which regulates anti-oxidant stress) and GATA-1 expression in erythroid precursor populations. In order to further improve the effects of RAP-536 (since it did not increase HbF), we evaluated the effects of RAP-536 combination with HU, TZM or FTX6058. First, we show that HU, TZM and FTX6058 induced HbF, with a synergistic effect observed only in RAP-536 and FTX6058 combination. Likewise, combination therapy with TZM or FTX6058 further enhanced RBC count, Ery.C cells and reduced reticulocyte counts and bilirubin levels. No additive or synergistic effect was observed to reduce ROS levels. In a hypoxia/re-oxygenation VOC model, the reduction of sickling observed with RAP-536 was additive with that observed with TZM or FTX6058. Conclusion These pre-clinical data highlight the potential of luspatercept (RAP-536) as a therapeutic agent in SCD, demonstrating significant improvements in ineffective erythropoiesis, reduction of hemolysis and ROS levels, and amelioration of VOC events independently of HbF induction. Effects on chronic complications are currently being investigated. The observed synergy with HbF inducers like HU, TZM and FTX6058 suggests potential combination strategies to enhance therapeutic outcomes. These findings warrant clinical evaluation of luspatercept in SCD patients, aiming to address both anemia and vaso-occlusive complications in this patient population with high unmet medical need.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.233
Teacher spread0.226 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicMicroRNA in disease regulation→French-language works237,207→